Fiscal Year Earnings Estimate on Arena Pharmaceuticals, Inc.(ARNA)

Arena Pharmaceuticals, Inc.(ARNA): For the most recent quarter end, Arena Pharmaceuticals, Inc. reported Annual Earnings of $-0.05. Based on the filings, last years Annual Earnings was, $-0.45. For the most recent quarter end, ARNA reported a surprise Earnings per Share of 28.57% . The consensus estimate for current quarter is $-0.09 and for the current fiscal year, the estimate is $-0.34. For the Next fiscal year, the estimate is $-0.31 based on the consensus.

Arena Pharmaceuticals, Inc. has received $-0.09 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 4 Financial Advisor in the Stock Trading Firms. Among 4 Analysts, Bottom line EPS Estimate for the current quarter is $-0.11 while the top line estimate is $-0.07 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 26.92%. Arena Pharmaceuticals, Inc. reported better than expected with a surprise EPS of 28.57% or $0.02 during its most recent quarterly earnings. The Actual EPS was $-0.05 compared to the Estimated EPS of $-0.07.

Arena Pharmaceuticals Last issued its quarterly earnings results on Nov 7, 2016. The company reported $-0.05 EPS for the quarter, beating the analyst consensus estimate by $ 0.02. Analyst had a consensus of $-0.07. The company had revenue of $19.20 million for the quarter, compared to analysts expectations of $16.57 million. The companys revenue was up 111.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.11 EPS.

Company has reported several Insider transactions to the SEC, on Jun 15, 2016, Christine Anna White (director) sold 18,728 shares at 1.99 per share price.On Apr 1, 2015, Randall E Woods (director) sold 76,268 shares at 4.49 per share price.On Mar 18, 2015, Steven W Spector (EVP, General Counsel & Sec) sold 70,000 shares at 5.00 per share price.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) witnessed a decline in the market cap on Wednesday as its shares dropped 2.07% or 0.03 points. After the session commenced at $1.45, the stock reached the higher end at $1.47 while it hit a low of $1.42. With the volume soaring to 910,973 shares, the last trade was called at $1.42. The company has a 52-week high of $2.16. The company has a market cap of $346 million and there are 243,400,800 shares in outstanding. The 52-week low of the share price is $1.3418.

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their first and only drug approved by any regulatory agency for marketing. BELVIQ was approved by the US Food and Drug Administration, or FDA, for marketing in the United States, and was made available by prescription in June 2013 to adults who are overweight with a comorbidity or obese. They are exploring BELVIQ for possible new indications, using different formulations, and in combination with other drugs.

Arena

Add Comment